Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 21.6% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 482,745 shares of the medical research company's stock after acquiring an additional 85,759 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.94% of Charles River Laboratories International worth $95,086,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of CRL. Tortoise Investment Management LLC lifted its position in shares of Charles River Laboratories International by 77.0% during the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company's stock worth $27,000 after buying an additional 57 shares during the last quarter. Wolff Wiese Magana LLC acquired a new stake in Charles River Laboratories International during the 3rd quarter worth $32,000. Assetmark Inc. lifted its position in Charles River Laboratories International by 1,153.3% in the third quarter. Assetmark Inc. now owns 188 shares of the medical research company's stock valued at $37,000 after acquiring an additional 173 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in Charles River Laboratories International in the third quarter valued at $59,000. Finally, Covestor Ltd increased its position in shares of Charles River Laboratories International by 40.9% during the third quarter. Covestor Ltd now owns 327 shares of the medical research company's stock worth $65,000 after purchasing an additional 95 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CRL has been the topic of a number of research reports. Bank of America dropped their price target on Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating on the stock in a research note on Friday, December 13th. Redburn Atlantic began coverage on shares of Charles River Laboratories International in a report on Monday, October 14th. They issued a "sell" rating and a $151.00 target price on the stock. StockNews.com cut shares of Charles River Laboratories International from a "buy" rating to a "hold" rating in a research note on Thursday, November 7th. TD Cowen lifted their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a "hold" rating in a research note on Monday, November 11th. Finally, Evercore ISI upped their price objective on Charles River Laboratories International from $190.00 to $225.00 and gave the company an "in-line" rating in a research note on Thursday, November 7th. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $214.00.

Insider Buying and Selling at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of the business's stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the transaction, the director now directly owns 12,386 shares of the company's stock, valued at $2,676,862.32. The trade was a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 1.30% of the company's stock.

Charles River Laboratories International Price Performance

CRL stock traded up $3.16 during trading on Friday, reaching $185.80. 408,850 shares of the company were exchanged, compared to its average volume of 447,125. Charles River Laboratories International, Inc. has a 52-week low of $176.48 and a 52-week high of $275.00. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. The company has a market cap of $9.50 billion, a P/E ratio of 23.25, a PEG ratio of 5.00 and a beta of 1.38. The stock's 50 day moving average price is $192.84 and its 200 day moving average price is $200.31.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, topping analysts' consensus estimates of $2.43 by $0.16. The business had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The company's revenue was down 1.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.72 EPS. As a group, analysts predict that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).